Absolute bioavailability of 2′-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 296, Issue 3, 2001, Pages 898-904

  Geary, Richard S ^a   Khatsenko, Oleg ^a   Bunker, Keith ^a   Crooke, Rosanne ^a   Moore, Max ^a   Burckin, Todd ^a   Truong, Loanne ^a   Sasmor, Henri ^a   Levin, Arthur A ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' O (2 METHOXYETHYL)PHOSPHOROTHIOATE OLIGONUCLEOTIDE; ALICAFORSEN; ANTISENSE OLIGONUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; ISIS 11159; ISIS 14725; ISIS 16952; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG STABILITY; DRUG TARGETING; GASTROINTESTINAL TRACT; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DRUG STABILITY; MALE; OLIGONUCLEOTIDES, ANTISENSE; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; THIONUCLEOTIDES;

EID: 0035119622     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Pharmacokinetics of antisense oligonucleotides
2. Pharmacokinetics and bioavailability of antisense oligonucleotides following oral and colorectal administrations in experimental animals
3. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
4. Caco-2 monolayers in experimental and theoretical predictions of drug transport
5. 2′-O-(2-methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells
6. Gastrointestinal absorption of drugs: Methods and studies
7. Antisense oligonucleotide-based therapeutics
8. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
9. Disposition of the 14C-labeled phosphorothioate oligonucleotide ISIS 2105 after intravenous administration to rats
10. Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats
11. Progress in antisense therapeutics
12. In vitro pharmacokinetics of phosphorothioate antisense oligonucleotides
13. Metabolism of antisense oligonucleotides in rat liver homogenates
14. Drug absorption. I. An in situ rat gut technique yielding realistic absorption rates
15. Antisense oligonucleotides to protein kinase C-α and C-raf kinase: Rationale and clinical experience in patients with solid tumors
16. Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expression
17. Pharmacokinetic properties of 2′-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats
18. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration
19. Absorption of antisense oligonucleotides in rat intestine: Effect of chemistry and length
20. The relationship between rat intestinal permeability and hydrophilic probe size
21. Quantitation of phosphorothioate oligonucleotides in human plasma
22. Toxicity of oligodeoxynucleotide therapeutic agents
23. Local administration of antisense phosphorothioate oligonucleotides to the p65 subunit of NF-kappa B abrogates established experimental colitis in mice
24. Pulmonary bioavailability of a phosphorothioate oligonucleotide (CGP 64128A): Comparison with other delivery routes
25. Pharmacokinetics, metabolism and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration
26. Shutting down a gene. Antisense drug wins approval
27. Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration
28. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of steroid-dependent Crohn's disease